immpact-international

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Covalent Bruton tyrosine kinase inhibitors (BTKis) and the BCL2 inhibitor venetoclax have significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL), especially those with biologically adverse disease. Patients with CLL resistant to their first targeted agent (TA) can be effectively treated with the alternative class. However, relapses are expected with second-line TA therapy, and the clinical challenge of double class-resistant disease is now emerging with increasing frequency. To define the characteristics and outcomes of patients with double class-resistant disease, we retrospectively analyzed 17 patients who developed progressive disease (PD) on both TA classes for CLL (venetoclax, then BTKi, n=12; BTKi, then venetoclax, n=5). The cohort was heavily pre-treated (median lines of prior therapy: 4) and enriched for adverse disease genetics (complex karyotype: 12/12 tested, 100%; del(17p)/TP53 mutations: 15/17, 88%). The median time to progression on prior venetoclax was 24 (range 6-94) months, and on prior BTKi was 25 (range 1-55) months. Progression on second-line TA was manifest as progressive CLL in 11 patients and as Richter transformation in six. The median overall survival after progression on second-line TA was 3.6 (95%CI 2-11) months. Patients with double class-resistant CLL have a dismal prognosis, representing a group of high unmet need.

Concerted hepatoprotective effect of bradykinin potentiating factor and low dose of γ- radiation on Naja haje envenomed rats via Bax/Bcl2 pathway

 

This study investigates the concerted hepatoprotective effects for three doses of bradykinin potentiating factor (BPF) and/or followed by exposure to a low dose of γ-radiation (LDR) against Naja haje envenoming in rats. Male rats were injected with three consecutive doses of BPF (1μg/g i.p. for 3 days), followed by exposure to a low dose of gamma radiation (0.5 Gy), and then rats were injected with a dose of Naja haje venom (250 μg/kg i.p.).
  • Results showed that Naja haje causes liver damage, significant elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), cytochrome c, Nitric oxide (NO), malondialdehyde (MDA) and significant depletion in glutathione peroxidase (GPx) contents. In addition, significant depletion in B-cell lymphoma 2 (Bcl-2) and significant elevation in BcL-2 associated X (Bax protein), nuclear factor kappa B (NF-κB), interleukin-1β (IL-1β) in hepatocytes.
  • Bradykinin potentiating factor and/or low dose of γ-radiation caused improvement in liver damage caused by Naja haje venom by a significant decrease in ALT, AST, ALP levels, Bax, cytochrome c, NF-κB, IL-1β, NO and MDA contents, BPF alone or combined with low dose radiation caused a significant increase in Bcl2 and GPx contents.In conclusion, the concerted impact of BPF and LDR may provide an effective venom detoxification tool that helps to reduce hepatic toxicity and extends the lifespan.

 

MYC, BCL2, and BCL6 expression as prognostic indicators in primary central nervous system lymphoma: A systematic review and meta-analysis

Background: We conducted a meta-analysis to comprehensively assess the predictive role of MYC, BCL2, and BCL6 genetic alterations and protein expression in PCNSL for clinical application.
Methods: A systematic retrieval was performed on PubMed, Embase, the Cochrane library, Web of Science, Scopus, and 2 Chinese databases. Cohort studies discussing the prognostic impact of MYC, BCl2, or BCL6 genetic alterations or gene expression in PCNSL were selected. The pooled hazard ratio (HR) and median survival ratio (MSR) were calculated.
Results: 31 studies involving 1739 patients fulfilled our inclusion criteria. MYC expression was significantly associated with short median OS (MSR = 0.62; 95%CI, 0.44-0.88) and PFS (HR = 1.53; 95%CI, 1.06-2.20). No significant association was found between BCL2 expression and OS or PFS (P > 0.05). BCL6 protein positivity was significantly associated with extended median OS (MSR = 1.62; 95%CI, 1.10-2.40).
MYC and BCL2 coexpression was significantly associated with short median OS (MSR = 0.61; 95%CI, 0.45-0.84). Subgroup analysis demonstrated that MYC protein positivity remained as a significant indicator for short median OS in studies whose sample size ≥ 45, treatment without WBRT, quality scale score ≥ 7, and positivity threshold set at 40% stratum (MSR < 1 and P < 0.05), but failed to reach a statistically significant difference in the other stratum.
Conclusions: MYC expression predicts inferior median OS and PFS in PCNSL. BCL6 protein positivity is associated with a favorable prognosis. The sample size, average age of subjects, WBRT treatment, study quality, and cut-off values for discriminating positive and negative protein expression in IHC may be origins of heterogeneity.
Keywords: BCL2; BCL6; Gene expression; MYC; Primary central nervous system lymphoma.
immpact-international
immpact-international

Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss

Melanomas driven by loss of the NF1 tumor suppressor have a high risk of treatment failure and effective therapies have not been developed. Here we show that loss-of-function mutations of nf1 and pten result in aggressive melanomas in zebrafish, representing the first animal model of NF1-mutant melanomas harboring PTEN loss. MEK or PI3K inhibitors show little activity when given alone due to cross-talk between the pathways, and high toxicity when given together.
The mTOR inhibitors, sirolimus, everolimus, and temsirolimus, were the most active single agents tested, potently induced tumor-suppressive autophagy, but not apoptosis. Because addition of the BCL2 inhibitor venetoclax resulted in compensatory upregulation of MCL1, we established a three-drug combination composed of sirolimus, venetoclax, and the MCL1 inhibitor S63845. This well-tolerated drug combination potently and synergistically induces apoptosis in both zebrafish and human NF1/PTEN-deficient melanoma cells, providing preclinical evidence justifying an early-stage clinical trial in patients with NF1/PTEN-deficient melanoma.

BCL2 inhibitors and MCL1 inhibitors for hematological malignancies

BCL2 and MCL1 are commonly expressed pro-survival (anti-apoptotic) proteins in hematological cancers and play important roles in their biology either through dysregulation or by virtue of intrinsic importance to the cell-of-origin of the malignancy. A new class of small molecule anti-cancer drugs, BH3-mimetics, now enable specific targeting of these proteins in patients.
BH3-mimetics act by inhibiting the pro-survival BCL2 proteins to enable the activation of BAX and BAK, apoptosis effectors which permeabilize the outer mitochondrial membrane, triggering apoptosis directly in many cells and sensitizing others to cell death when combined with other anti-neoplastic drugs. Venetoclax, a specific inhibitor of BCL2, is the first approved in class, demonstrating striking single agent activity in chronic lymphocytic leukemia (CLL) and in other lymphoid neoplasms, as well as activity against acute myeloid leukemia (AML), especially when used in combination.
Key insights from the venetoclax experience include that responses occur rapidly, with major activity as monotherapy proving to be the best indicator for success in combination regimens. This emphasizes the importance of adequate single agent studies for drugs in this class. Furthermore, secondary resistance is common with long-term exposure and often mediated by genetic or adaptive changes in the apoptotic pathway, suggesting that BH3-mimetics are better suited to limited-duration, rather than continuous, therapy. The success of venetoclax has inspired development of BH3-mimetics targeting MCL1. Despite promising preclinical activity against MYC-driven lymphomas, myeloma and AML, their success may particularly depend on their tolerability profile given physiological roles for MCL1 in several non-hematological tissues.

Recombinant Human Polyadenylate-Binding Protein-Interacting Protein 2

7-05799 1mg Ask for price

Polyadenylate-Binding Protein 2 (PABPN1) Antibody

20-abx004649
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Polyadenylate-Binding Protein 2 (PABPN1) Antibody

abx029099-400ul 400 ul
EUR 627.6

Polyadenylate-Binding Protein 2 (PABPN1) Antibody

abx029099-80l 80 µl
EUR 343.2

Polyadenylate-Binding Protein 2 (PABPN1) Antibody

20-abx217614
  • EUR 510.00
  • EUR 410.40
  • 100 ug
  • 50 ug

Bovine Polyadenylate- binding protein 1, PABPC1 ELISA KIT

ELI-12383b 96 Tests
EUR 1113.6

Polyadenylate-Binding Protein-Interacting Protein 2 Protein

20-abx260556
  • EUR 3433.20
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 25 ug
  • 5 ug

Polyadenylate-Binding Protein-Interacting Protein 2 Antibody

20-abx137383
  • EUR 844.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 20 ug
  • 5 ug

PAIP2 Polyadenylate-Binding Protein-Interacting protein 2 Human Recombinant Protein

PROTQ9BPZ3 Regular: 25ug
EUR 380.4
Description: Recombinant Human PAIP2 produced in E.Coli is a single,non-glycosylated polypeptide chain containing 147 amino acids (1-127 a.a.) and having a molecular mass of 17.1 kDa.;PAIP2 human recombinant is fused to 20 amino acid His Tag at N-terminus and purified by convential chromatogrpahy techniques.

Polyadenylate-Binding Protein 1-Like 2 (PABPC1L2B) Antibody

abx030671-400ul 400 ul
EUR 627.6

Polyadenylate-Binding Protein 1-Like 2 (PABPC1L2B) Antibody

abx030671-80l 80 µl
EUR 343.2

Mouse Polyadenylate- binding protein 2, Pabpn1 ELISA KIT

ELI-35520m 96 Tests
EUR 1038

Human Polyadenylate- binding protein 2, PABPN1 ELISA KIT

ELI-21970h 96 Tests
EUR 988.8

Human Polyadenylate-binding protein 1 (PABPC1)

1-CSB-EP017352HU
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Polyadenylate-binding protein 1(PABPC1),partial expressed in E.coli

Polyadenylate-Binding Protein 4-Like (PABPC4L) Antibody

abx028778-400ul 400 ul
EUR 627.6

Polyadenylate-Binding Protein 4-Like (PABPC4L) Antibody

abx028778-80l 80 µl
EUR 343.2

Arabidopsis thaliana Polyadenylate-binding protein RBP47A (RBP47A)

1-CSB-EP522272DOA
  • EUR 733.20
  • EUR 370.80
  • EUR 2192.40
  • EUR 1126.80
  • EUR 1461.60
  • EUR 476.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Arabidopsis thaliana Polyadenylate-binding protein RBP47A(RBP47A) expressed in E.coli

Recombinant Human Polyadenylate-binding protein 1, His-SUMO, E.coli-100ug

QP6461-ec-100ug 100ug
EUR 489.6

Recombinant Human Polyadenylate-binding protein 1, His-SUMO, E.coli-10ug

QP6461-ec-10ug 10ug
EUR 240

Recombinant Human Polyadenylate-binding protein 1, His-SUMO, E.coli-1mg

QP6461-ec-1mg 1mg
EUR 1958.4

Recombinant Human Polyadenylate-binding protein 1, His-SUMO, E.coli-200ug

QP6461-ec-200ug 200ug
EUR 760.8

Recombinant Human Polyadenylate-binding protein 1, His-SUMO, E.coli-500ug

QP6461-ec-500ug 500ug
EUR 1272

Recombinant Human Polyadenylate-binding protein 1, His-SUMO, E.coli-50ug

QP6461-ec-50ug 50ug
EUR 315.6

Human Polyadenylate-Binding Protein 1 (PABPC1) ELISA Kit

abx259760-96tests 96 tests
EUR 1093.2

Human Polyadenylate- binding protein 3, PABPC3 ELISA KIT

ELI-43230h 96 Tests
EUR 988.8

Human Polyadenylate- binding protein 4, PABPC4 ELISA KIT

ELI-35673h 96 Tests
EUR 988.8

Mouse Polyadenylate- binding protein 1, Pabpc1 ELISA KIT

ELI-21806m 96 Tests
EUR 1038

Human Polyadenylate- binding protein 5, PABPC5 ELISA KIT

ELI-21807h 96 Tests
EUR 988.8

Human Polyadenylate- binding protein 1, PABPC1 ELISA KIT

ELI-12384h 96 Tests
EUR 988.8

Bovine KIDNEY WHOLE 2 EA*

57120-2 2 EA
EUR 209.81

Bovine TNF alpha Recombinant

R00002-2 5ug/vial
EUR 310.8
Description: Tumor necrosis factor alpha (TNFSF2, TNF alpha) is a member of the TNF Superfamily. TNF alpha, being an endogenous pyrogen, is able to induce fever, to induce apoptotic cell death, to induce sepsis (through IL-1 & IL-6 production), to induce cachexia, induce inflammation, and to inhibit tumorigenesis and viral replication. Bovine TNF alpha Recombinant Protein is purified TNF alpha (TNFSF2) produced in yeast.

Human Polyadenylate- binding protein 4- like, PABPC4L ELISA KIT

ELI-21969h 96 Tests
EUR 988.8

Human Polyadenylate- binding protein 1- like, PABPC1L ELISA KIT

ELI-14688h 96 Tests
EUR 988.8

ELISA kit for Human Polyadenylate-binding protein 1-like (PABPC1L)

KTE61322-48T 48T
EUR 398.4
Description: Quantitative sandwich ELISA for measuring Human Polyadenylate-binding protein 1-like (PABPC1L) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Human Polyadenylate-binding protein 1-like (PABPC1L)

KTE61322-5platesof96wells 5 plates of 96 wells
EUR 2538
Description: Quantitative sandwich ELISA for measuring Human Polyadenylate-binding protein 1-like (PABPC1L) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Human Polyadenylate-binding protein 1-like (PABPC1L)

KTE61322-96T 96T
EUR 646.8
Description: Quantitative sandwich ELISA for measuring Human Polyadenylate-binding protein 1-like (PABPC1L) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Nori Bovine A1AT ELISA Kit-2 Plates

GR112012-2 2 x 96-well
EUR 998.4

Nori Bovine A1PI ELISA Kit-2 Plates

GR112013-2 2 x 96-well
EUR 998.4

Nori Bovine LDHA ELISA Kit-2 Plates

GR112014-2 2 x 96-well
EUR 998.4

Recombinant Bovine Growth Hormone Binding Protein

7-00523 5µg Ask for price

Recombinant Bovine Growth Hormone Binding Protein

7-00524 20µg Ask for price

Recombinant Bovine Growth Hormone Binding Protein

7-00525 1mg Ask for price

Recombinant Bovine Growth Hormone Binding Protein

CG042-100 100ug
EUR 740.4

Recombinant Bovine Growth Hormone Binding Protein

CG042-101 1mg
EUR 3138

Recombinant Bovine Growth Hormone Binding Protein

CG042-200 200ug
EUR 1048.8

Nori Bovine MMP-3 ELISA Kit (2 plates)

GR112027-2 2 x 96-well
EUR 998.4

Nori® Bovine BDNF ELISA Kit- 2 Plates

GR112038-2 2 x 96-well
EUR 998.4

GSI Bovine (cattle) UCP2 ELISA Kit (2 plates)

GR112039-2 2 x 96-well
EUR 998.4

Nori® Bovine HGF ELISA Kit- 2 Plates

GR112046-2 2 x 96-well
EUR 998.4

Human Polyadenylate-binding protein 1 (PABPC1) control (non-asymmetric methylated) peptide

AB-23051-CP 100ug
EUR 196.8

Human Polyadenylate-binding protein 1 (PABPC1) control (PABPC1- asymmetric methylated) peptide

AB-23051-P 100ug
EUR 196.8

Bovine Odorant-binding protein

1-CSB-MP362133BO
  • EUR 466.80
  • EUR 1672.80
  • EUR 675.60
  • EUR 1230.00
  • 100ug
  • 1MG
  • 200ug
  • 500ug
Description: Recombinant Bovine Odorant-binding protein expressed in Mammalian cell

Bovine Odorant-binding protein

1-CSB-BP362133BO
  • EUR 1008.00
  • EUR 398.40
  • EUR 2604.00
  • EUR 1362.00
  • EUR 1894.80
  • EUR 564.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Bovine Odorant-binding protein expressed in Baculovirus

Bovine Odorant-binding protein

1-CSB-EP362133BO
  • EUR 745.20
  • EUR 457.20
  • EUR 2331.60
  • EUR 1058.40
  • EUR 1602.00
  • EUR 541.20
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Bovine Odorant-binding protein expressed in E.coli

Bovine Odorant-binding protein

1-CSB-YP362133BO
  • EUR 954.00
  • EUR 541.20
  • EUR 2745.60
  • EUR 1400.40
  • EUR 1869.60
  • EUR 661.20
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Bovine Odorant-binding protein expressed in Yeast

Bovine Odorant-binding protein

1-CSB-YP362133BOa0
  • EUR 814.80
  • EUR 402.00
  • EUR 2606.40
  • EUR 1261.20
  • EUR 1730.40
  • EUR 522.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Bovine Odorant-binding protein expressed in Yeast

Bovine Odorant-binding protein

1-CSB-YP362133BOa4
  • EUR 814.80
  • EUR 402.00
  • EUR 2606.40
  • EUR 1261.20
  • EUR 1730.40
  • EUR 522.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Bovine Odorant-binding protein expressed in Yeast

Bovine Odorant-binding protein

1-CSB-YP362133BOb0
  • EUR 814.80
  • EUR 402.00
  • EUR 2606.40
  • EUR 1261.20
  • EUR 1730.40
  • EUR 522.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Bovine Odorant-binding protein expressed in Yeast

Nori® Bovine (cow) TLR3 ELISA Kit (2 plates)

GR106082-2 2 x 96-well
EUR 998.4

Nori® Bovine (cow) BMP1 ELISA Kit (2 plates)

GR106213-2 2 x 96-well
EUR 998.4

Nori® Bovine (cow) BMP2 ELISA Kit (2 plates)

GR106214-2 2 x 96-well
EUR 998.4

Nori® Bovine (cow) BMP3 ELISA Kit (2 plates)

GR106215-2 2 x 96-well
EUR 998.4

Nori® Bovine (cow) BMP4 ELISA Kit (2 plates)

GR106216-2 2 x 96-well
EUR 998.4

Nori® Bovine (cow) BMP5 ELISA Kit (2 plates)

GR106217-2 2 x 96-well
EUR 998.4

Nori® Bovine (cow) BMP6 ELISA Kit (2 plates)

GR106218-2 2 x 96-well
EUR 998.4

Nori® Bovine (cow) BMP7 ELISA Kit (2 plates)

GR106219-2 2 x 96-well
EUR 998.4

Nori® Bovine (cow) BMP8a ELISA Kit (2 plates)

GR106220-2 2 x 96-well
EUR 998.4

Nori® Bovine IL-10 ELISA Kit (2 plates)

GR106295-2 2 x 96-well
EUR 998.4

Nori® Bovine Erythropoietin R ELISA Kit (2 plates)

GR106439-2 2 x 96-well
EUR 998.4

Nori® Bovine PKA C ELISA Kit- 2 Plates

GR112034-2 2 x 96-well
EUR 998.4

Nori® Bovine TLR-9 ELISA Kit- 2 Plates

GR112041-2 2 x 96-well
EUR 998.4

Nori® Bovine IL-12 ELISA Kit- 2 Plates

GR112042-2 2 x 96-well
EUR 998.4

Nori® Bovine IL-5 ELISA Kit- 2 Plates

GR112045-2 2 x 96-well
EUR 998.4

Nori® Bovine PDGF-AA ELISA Kit- 2 Plates

GR112048-2 2 x 96-well
EUR 998.4

Nori® Bovine PDGF-BB ELISA Kit- 2 Plates

GR112049-2 2 x 96-well
EUR 998.4

Recombinant Human BD-2 Protein

PROTO15263-2 20ug
EUR 380.4
Description: Defensins (alpha and beta) are cationic peptides with a broad spectrum of antimicrobial activity that comprise an important arm of the innate immune system. The α-defensins are distinguished from the β-defensins by the pairing of their three disulfide bonds. To date, six human β-defensins have been identified; BD-1, BD-2, BD-3, BD-4, BD-5 and BD-6. β-defensins are expressed on some leukocytes and at epithelial surfaces. In addition to their direct antimicrobial activities, they can act as chemoattractants towards immature dendritic cells and memory T cells. The β-defensin proteins are expressed as the C-terminal portion of precursors and are released by proteolytic cleavage of a signal sequence and in some cases, a propeptide sequence. β-defensins contain a six-cysteine motif that forms three intra-molecular disulfide bonds. Recombinant human BD-2 is a 4.3 kDa protein containing 41 amino acid residues.

Recombinant Human Relaxin-2 Protein

PROTP04090-2 25ug
EUR 380.4
Description: Relaxin-2 is a peptide hormone structurally related to insulin, which is expressed in the placenta, decidua, prostate, and in the ovary during pregnancy. Of the three known relaxin genes, Relaxin-2 is the only relaxin known to circulate in the blood. Relaxin-2 binds specifically to the LGR7 and LGR8 receptors, previously identified as an “orphan” G protein coupled receptors. Signaling by Relaxin-2 through its target receptors enhances the growth of pubic ligaments and ripening of the cervix during birth. Recombinant Relaxin-2 is a nonglycosylated 6.0 kDa disulfide linked heterodimeric protein consisting of a 24 amino acid A-chain and a 29 amino acid B-chain.

Recombinant Murine IL-2 Protein

PROTP04351-2 20ug
EUR 380.4
Description: IL-2 is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. IL-2/IL-2R signaling is required for T-cell proliferation and other fundamental functions which are essential for the immune response. IL-2 stimulates growth and differentiation of B-cells, NK cells, lymphokine activated killer cells, monocytes, macrophages and oligodendrocytes. Recombinant murine IL-2 is a 17.2 kDa protein, containing 149 amino acid residues.

Recombinant Human PAI-2 Protein

PROTP05120-2 10ug
EUR 380.4
Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa nonglycosylated intracellular protein which can be induced to be secreted as 60 kDa glycoprotein. The glycosylated and unglycosylated forms of PAI-2 are equally effective as inhibitors of urokinase-type plasminogen activator (uPA), the only established physiological target of this serpin. PAI-2 has a unique ability to form dormant polymers spontaneously and reversibly under physiological conditions. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant human PAI-2 is a 415-residue nonglycosylated protein.

Recombinant Human MMP-2 Protein

PROTP08253-2 10ug
EUR 380.4
Description: Matrix metalloproteinases (MMPs) are a family of endoproteases that require zinc and calcium for expressing catalytic activity. These enzymes play a central role in the maintenance and remodeling of the extracellular matrix. Elevated expression of their activity, caused either by up-regulation of their expression or down-regulation of their cognate inhibitors, has been implicated in various degenerative disorders, including arthritis, cardiovascular disease, skeletal growth-plate disorders, and cancer metastasis. MMP-2 is a secreted collagenase with specificity toward Type IV, V, VII, and X collagens. Recombinant human MMP-2 is a 62.0 kDa protein containing the entire catalytic N-terminal domain and the C-terminal domain (552 amino acids).

Recombinant Human TFF-2 Protein

PROTQ03403-2 20ug
EUR 380.4
Description: The Trefoil Factor peptides (TFF1, TFF2 and TFF3) are expressed in the gastrointestinal tract, and appear to play an important role in intestinal mucosal defense and repair. TFF2 has been shown to inhibit gastrointestinal motility and gastric acid secretion. Recent data suggests a potential role for TFF2 in acute and chronic asthma (Nikolaidis, N.M. et al. Am. Journal Respir. Cell Mol. Biol. (2003) 4: 458-464). Recombinant human TFF2 is a 12.0 kDa polypeptide of 107 amino acid residues, which includes a 40-amino acid trefoil motif containing three conserved intramolecular disulfide bonds.

Mouse FGF-2 Recombinant Protein

R00121-2 5ug/vial
EUR 310.8
Description: FGF basic (FGF2) is a multipotential fibroblast growth factor that stimulates and supports proliferation, migration and differentiation. Mouse FGF basic (FGF-2) Recombinant Protein is purified FGF basic (FGF-2) produced in yeast.

Chicken IL-2 Recombinant Protein

R00387-2 5ug/vial
EUR 310.8
Description: Interleukin-2 (IL-2) is a cytokine produced by T-helper cells in response to antigenic or mitogenic stimulation. It is required for T-cell proliferation and other activities crucial to the regulation of the immune response. Chicken IL-2 Recombinant Protein is purified interleukin-2 produced in yeast.

BMP-2 Bone Morphogenetic Protein-2 Human Recombinant Protein, Monomer

PROTP12643-2 Regular: 20ug
EUR 380.4
Description: Bone Morphogenetic Protein-2 Human Recombinant produced in E.Coli is a monomeric, non-glycosylated, Polypeptide chain containing 115 amino acids (283-396) and having a molecular mass of 13009 Dalton. ;The BMP-2 is purified by proprietary chromatographic techniques.

Nori® Bovine PKA C-alpha ELISA Kit- 2 Plates

GR112035-2 2 x 96-well
EUR 998.4

Nori® Bovine PKA RI-beta ELISA Kit- 2 Plates

GR112036-2 2 x 96-well
EUR 998.4

Nori® Bovine IL-18 BPa ELISA Kit-2 Plates

GR112069-2 2 x 96-well
EUR 998.4

Nori® Bovine Cyclophilin A (CyPA) ELISA Kit-2 Plates

GR112076-2 2 x 96-well
EUR 998.4

Nori® Bovine Cyclophilin B (CyPB) ELISA Kit-2 Plates

GR112077-2 2 x 96-well
EUR 998.4

Bovine Hyaluronan- binding protein 2, HABP2 ELISA KIT

ELI-43906b 96 Tests
EUR 1113.6

Bovine Synaptojanin- 2- binding protein, SYNJ2BP ELISA KIT

ELI-39606b 96 Tests
EUR 1113.6

Bovine Calcium- binding protein 2, CABP2 ELISA KIT

ELI-11095b 96 Tests
EUR 1113.6